Decision making and dementia: from mechanisms to clinical trials
Lead Research Organisation:
University of Cambridge
Department Name: UNLISTED
Abstract
For people with dementia and related conditions, the changes in memory and behaviour not only affect quality of life but also survival. We study the causes and potential treatments of the changes in behaviour and thinking that affect people with dementia. Rather than look only at the root cause of disease (which is often not known), we look at what is happening in the human brain to change behaviour. In practical terms this could be a better basis for treatment than trying to reverse the effects of faulty genes or unknown environmental triggers. We work with people with different conditions, including Alzheimer’s disease and frontotemporal lobar degeneration, and those with the risk of dementia because of faulty genes of ageing. Part 1 of the research aims to understand and restore behaviour, including the actions one takes and the decisions that lie behind those actions. Apathy and impulsivity are of particular interest. These two problems paradoxically often come together. They point to a worse prognosis. And they have possible treatments to hand. We use computational models of the brain to study how decisions are made in the brain, about what to do and what not to do. We link these models to actual brain function (physiology) and brain chemistry (pharmacology). With these methods, we explain why people differ in their symptoms and response to treatment. We call this precision medicine: precision not in terms of gene or molecules of the brain, but precision of the chemical, physiological and cognitive processes underlying dementia. Part 2 looks at brain function more closely. We use very big sets of data from collaborations (eg. MRC Dementias Platform UK and BIOFIND consortium), and specialist studies at the CBU (eg. Cambridge Centre for Ageing and Neuroscience and scans from people with Alzheimer’s disease, frontotemporal dementia, Progressive Supranuclear Palsy). We use these data to understand how and when dementia begins, and combine different types of brain scanning to explain the biological causes of dementia in people. This leads naturally to ways to target treatments at those most likely to respond.
Technical Summary
The program aims to improve cognition, survival and quality of life of those affected by neurodegenerative disease. It focuses on neurocognitive systems which are proximate to the clinical phenotypes caused by Alzheimer’s disease and frontotemporal lobar degeneration, in the context of normal ageing.
Part 1 seeks to understand and restore behaviours, that are common to many dementias and movement disorders. The term behaviour encompasses the actions one takes and the decisions or goals that lie behind those actions. Apathy and impulsivity are of particular interest, because of their paradoxical positive correlation in disease, their prognostic significance, and their readiness for symptomatic trials. In this program, we formalise behaviour as decisions to act vs to not act (including inhibition) in two complementary types of model: first, the accumulation-to-threshold of the neural basis of evidence; and second, the dynamics of hierarchical networks implementing inferences and predictions of the causes of sensory inputs. The context in which decisions are made is critical, and the program therefore distinguishes transient sensory evidence from enduring contextual beliefs and their predictions. By linking these models to physiological and pharmacological systems, we move towards precision medicine: precision not in terms of gene or molecular aetiology but precision of the chemical, physiological and cognitive processes underlying dementia phenotypes.
Part 2 develops the concept of cognitive physiology further, in terms of generative models of brain function. We draw on large scale data from collaborations (eg. MRC Dementias Platform UK synaptic health theme, Deep and Frequent Phenotyping study, BIOFIND consortium), and CBU based programs (eg. Cambridge Centre for Ageing and Neuroscience and clinical series of Alzheimer’s disease, frontotemporal dementia, Progressive Supranuclear Palsy). The framework of dynamic causal modelling is used to integrate modalities (magnetoencephalography, 7T-MR spectroscopy, PET markers of pathology) to explain phenotypic heterogeneity, identify common mechanisms, and predict treatment response.
Part 1 seeks to understand and restore behaviours, that are common to many dementias and movement disorders. The term behaviour encompasses the actions one takes and the decisions or goals that lie behind those actions. Apathy and impulsivity are of particular interest, because of their paradoxical positive correlation in disease, their prognostic significance, and their readiness for symptomatic trials. In this program, we formalise behaviour as decisions to act vs to not act (including inhibition) in two complementary types of model: first, the accumulation-to-threshold of the neural basis of evidence; and second, the dynamics of hierarchical networks implementing inferences and predictions of the causes of sensory inputs. The context in which decisions are made is critical, and the program therefore distinguishes transient sensory evidence from enduring contextual beliefs and their predictions. By linking these models to physiological and pharmacological systems, we move towards precision medicine: precision not in terms of gene or molecular aetiology but precision of the chemical, physiological and cognitive processes underlying dementia phenotypes.
Part 2 develops the concept of cognitive physiology further, in terms of generative models of brain function. We draw on large scale data from collaborations (eg. MRC Dementias Platform UK synaptic health theme, Deep and Frequent Phenotyping study, BIOFIND consortium), and CBU based programs (eg. Cambridge Centre for Ageing and Neuroscience and clinical series of Alzheimer’s disease, frontotemporal dementia, Progressive Supranuclear Palsy). The framework of dynamic causal modelling is used to integrate modalities (magnetoencephalography, 7T-MR spectroscopy, PET markers of pathology) to explain phenotypic heterogeneity, identify common mechanisms, and predict treatment response.
Organisations
- University of Cambridge (Lead Research Organisation)
- MRC Dementias Platform UK (Collaboration)
- AC Immune (Collaboration)
- Ferrer Internacional (Collaboration)
- CARDIFF UNIVERSITY (Collaboration)
- University of California, San Francisco (Collaboration)
- Utrecht University (Collaboration)
- University of Glasgow (Collaboration)
- AstraZeneca (Collaboration)
- OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- University of Oxford (Collaboration)
- Boostec (Collaboration)
- King's College London (Collaboration)
- Ludwig Maximilian University of Munich (LMU Munich) (Collaboration)
- University of Southern California (Collaboration)
- Life Molecular Imaging (Collaboration)
- Alector (Collaboration)
- ALZHEIMER'S RESEARCH UK (Collaboration)
- University of Gothenburg (Collaboration)
- UK Dementia Research Institute (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- VU University Medical Center (Collaboration)
- NATIONAL INSTITUTE FOR HEALTH RESEARCH (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- McGill University (Collaboration)
- JOHNSON & JOHNSON (Collaboration)
- Eli Lilly & Company Ltd (Collaboration)
- University of Hong Kong (Collaboration)
- Irish Critical Care Clinical Trials Network (Collaboration)
- UNIVERSITY COLLEGE LONDON (Collaboration)
- University of Edinburgh (Collaboration)
- University of Toronto (Collaboration)
Publications
Anand T
(2024)
Drawing from name in semantic dementia reveals graded object knowledge representations in anterior temporal lobe.
in Memory & cognition
Borrego-Ecija S
(2024)
Association of Initial Side of Brain Atrophy With Clinical Features and Disease Progression in Patients With GRN Frontotemporal Dementia.
in Neurology
Böken D
(2024)
Single-Molecule Characterization and Super-Resolution Imaging of Alzheimer's Disease-Relevant Tau Aggregates in Human Samples.
in Angewandte Chemie (International ed. in English)
Böken D
(2024)
Single-Molecule Characterization and Super-Resolution Imaging of Alzheimer's Disease-Relevant Tau Aggregates in Human Samples
in Angewandte Chemie
Davenport F
(2023)
Neurodegenerative disease of the brain: a survey of interdisciplinary approaches.
in Journal of the Royal Society, Interface
Dimitri G
(2023)
Multimodal and multicontrast image fusion via deep generative models
| Title | Concert for dementia and Parkinson's research at Jesus College - Conversation with James B Rowe |
| Description | Concert for dementia and Parkinson's research at Jesus College Jesus College recently hosted a concert for dementia and Parkinson's disease research at the University of Cambridge, led by Professor Matt Lambon-Ralph, Director of the MRC Cognition and Brain Sciences Unit. The event highlighted the current understanding of and research into treating dementia and Parkinson's disease, with musical interludes providing space for calm reflection. Professor Lambon-Ralph opened the evening with a warm welcome, encouraging the audience to consider the experience of dementia and Parkinson's by outlining the symptoms of the diseases. |
| Type Of Art | Performance (Music, Dance, Drama, etc) |
| Year Produced | 2024 |
| Impact | Jesus College recently hosted a concert for dementia and Parkinson's disease research at the University of Cambridge, led by Professor Matt Lambon-Ralph, Director of the MRC Cognition and Brain Sciences Unit. The event highlighted the current understanding of and research into treating dementia and Parkinson's disease, with musical interludes providing space for calm reflection. |
| URL | https://www.jesus.cam.ac.uk/articles/concert-dementia-and-parkinsons-research-jesus-college |
| Description | 10 Downing Street Launch of Dementia Mission |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Impact | DPUK Director John Gallacher (PhD AFBPsS CPsychol FFPH) and DPUK Associate Directors Vanessa Raymont and James Rowe came together alongside charities, investors, industry and people living with or caring for those with dementia to accelerate efforts to tackle the disease. Obtaining and using complex data, speeding up clinical trials and the importance of biomarkers all support the mission to develop innovative research tools to tackle dementia. The mission provides a great opportunity for the UK to build at pace and scale and deliver meaningful change for people living with or at risk of this cruel disease. |
| URL | https://www.dementiasplatform.uk/news-and-media/latest-news/dpuk-at-no-10-to-support-dame-barbara-wi... |
| Description | Control Processes Meeting |
| Geographic Reach | National |
| Policy Influence Type | Contribution to new or improved professional practice |
| Impact | Control processes |
| Description | DPUK Work Package Forum |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | UKRI funded programme with measured impact. |
| Description | Dementia Mission No 10 Downing street |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Impact | Major impact on public-private partnership for dementia, policy and co-investing |
| Description | Dr M Perquin (Rowe Group) Member Society for Mathematical Psychology |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Dr M Perquin (Rowe Group) Member Society for Mathematical Psychology |
| Description | Dr M Perquin (Rowe Group) Member Women of Mathematical Psychology |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | • Became member of the professional organisation Women of Math Psych. |
| Description | FTDUK National Meeting |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Meeting of experts and training of researchers, engagement with public. |
| URL | https://www.ftduk.org/previous-programmes/#1727337659512-220c5b1a-1835 |
| Description | GENFI - Barcelona Meeting |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Academic and PPIE engagement. |
| Description | How to target good scientific problem - Dr Amirhossein Jafarian (Rowe Group) |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | PhD training |
| Description | MEG in Pharma |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Using MEG as an effective outcome measure in clinical trials. |
| Description | MHRA advisory committee |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | approval of new anti-alzheimer medications for the UK |
| Description | Medical and Health Regulatory Agency (MHRA) - Evidence on New Drugs for Dementia |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Policy workshop on UK drug landscape for Dementia. |
| Description | OLS-DIG Dementia scoping |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Impact | Decision taken to establish the Neurodegeneration initiative within the Dame Barbara Wilson Dementia Mission |
| Description | Prof. James B Rowe Policy national review committee (MHRA UK) |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Impact | MHRA, UK Advisory |
| Description | Sceintific Advisory Board Meber for AI-MIND |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| URL | https://www.ai-mind.eu/partners/ |
| Description | Scientific Advisory Board - AI Mind International Consortium |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Training and incorporation of AI. |
| Description | Scientific Advisory Board - Dementia Mission |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | DPUK Director John Gallacher (PhD AFBPsS CPsychol FFPH) and DPUK Associate Directors Vanessa Raymont and James Rowe came together alongside charities, investors, industry and people living with or caring for those with dementia to accelerate efforts to tackle the disease. Obtaining and using complex data, speeding up clinical trials and the importance of biomarkers all support the mission to develop innovative research tools to tackle dementia. The mission provides a great opportunity for the UK to build at pace and scale and deliver meaningful change for people living with or at risk of this cruel disease. |
| URL | https://www.dementiasplatform.uk/news-and-media/latest-news/dpuk-at-no-10-to-support-dame-barbara-wi... |
| Description | Sports Concussion Research Forum Member |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | See report https://www.ukri.org/wp-content/uploads/2024/09/MRC-120924-ConcussionInSportReport.pdf |
| URL | https://www.ukri.org/wp-content/uploads/2024/09/MRC-120924-ConcussionInSportReport.pdf |
| Description | US Food and Drug Agency Roundtable Meeting |
| Geographic Reach | North America |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Influence on Federal Agency. |
| Description | Addenbrooke's Charitable Trust |
| Amount | £59,172 (GBP) |
| Organisation | Addenbrooke's Charitable Trust (ACT) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2023 |
| End | 03/2024 |
| Description | Alzheimer's Research UK East Network Grant |
| Amount | £913 (GBP) |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2023 |
| End | 07/2023 |
| Description | Investigating the effect of deprivation in the dementia syndromes associated with frontotemporal lobar degeneration and Parkin's disease |
| Amount | £0 (GBP) |
| Funding ID | NIHR-INF-2586 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2023 |
| End | 03/2025 |
| Description | READOUT Real world dementia outcomes |
| Amount | £4,497,000 (GBP) |
| Funding ID | tbc |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2024 |
| End | 06/2029 |
| Description | SYNAPSE-FTLD: Design and delivery of clinical trials to treat challenging behaviours in the syndromes associated with frontotemporal lobar degeneration |
| Amount | £684,363 (GBP) |
| Funding ID | RAD-2023-Full 1002 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2025 |
| End | 01/2030 |
| Description | University of Cambridge/Montreal Neurological Institute-Hospital Neuroscience Collaboration - Dr M Malpetti (Rowe Group) |
| Amount | $50,000 (CAD) |
| Organisation | University of Montreal |
| Department | Montreal Neurological Institute |
| Sector | Hospitals |
| Country | Canada |
| Start | 11/2023 |
| End | 02/2025 |
| Title | Cambridge Questionnaire for Apathy and Impulsivity Traits - Rebeccca Williams |
| Description | The CamQUAIT (Cambridge Questionnaire for Apathy and Impulsivity Traits) spearheaded by Claire Lansdall was finally published this year - you can find the preprint here and we're currently submitting to PLOS ONE. |
| Type Of Material | Physiological assessment or outcome measure |
| Year Produced | 2024 |
| Provided To Others? | Yes |
| Impact | The CamQUAIT (Cambridge Questionnaire for Apathy and Impulsivity Traits) spearheaded by Claire Lansdall was finally published this year - you can find the preprint here and we're currently submitting to PLOS ONE. |
| URL | https://www.medrxiv.org/content/10.1101/2024.07.01.24309762v1 |
| Title | BioFIND |
| Description | MEG data in MCI/AD |
| Type Of Material | Database/Collection of data |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | Analysis development for neurophysiological biomarkers of dementia |
| URL | https://data.dpuk.ukserp.ac.uk/cohortdirectory/Item?fingerPrintID=BioFIND |
| Description | 11.7 UHUF national imaging facility |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | A new UKRI infrastructure award, led by Nottingham University, to establish a new 11.7 T MRI centre. Our role included the case for dementia and Parkinson's disease applications of the new technology; |
| Collaborator Contribution | A multicentre UK consortium, led by Nottingham, for technical, physics, manufacturing and medical impact of the world-leading facility |
| Impact | Award made. Planning ongoing to realise the physical infrastructure. |
| Start Year | 2021 |
| Description | Collaboration Tsvetanov KA & Virginia Newcombe "Understanding the pathogenesis of traumatic vascular injury" |
| Organisation | University of Cambridge |
| Department | Department of Clinical Neurosciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI: Virginia Newcombe Title: "Understanding the pathogenesis of traumatic vascular injury" Start date: 01/11/2022 Funding body: Brain Research UK Amount: £292,065 |
| Collaborator Contribution | Collaboration with Prof. Newcombe who received funiding from Brain Research UK. |
| Impact | Funding recieved. |
| Start Year | 2022 |
| Description | Collaboration with Dr Ece Kocagoncu for NTAD (Dr A Jafarian) |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration on data analysis of test-retest data from NTAD. |
| Collaborator Contribution | Availability of NTAD data. |
| Impact | Title: Test-reTest reliability of dynamic casual modelling of resting states MEG data of Alzheimer patients. |
| Start Year | 2022 |
| Description | Collaboration with Dr Nicholas Ashton at the University of Gothenburg |
| Organisation | University of Gothenburg |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | "Synaptic fluid markers in dementia", sharing expertise in field. |
| Collaborator Contribution | "Synaptic fluid markers in dementia", sharing expertise in field. |
| Impact | Advancing biomarker discovery projects. |
| Start Year | 2022 |
| Description | Collaboration with Dr. Gil Rabinovici at the Memory and Aging Center, Department of Neurology, University California San Francisco |
| Organisation | University of California, San Francisco |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collaboration on project "Tau-PET and domain-specific cognitive decline in Alzheimer's disease", cross fertilization of research expertise. |
| Collaborator Contribution | Hosted Post-Doc Dr M. malpetti for 4 month fellowship at UCSF. |
| Impact | Reasearch paper: Malpetti M, La Joie R, Rabinovici GD. Tau beats amyloid in predicting brain atrophy in Alzheimer's disease: implications for prognosis and clinical trials. 2022, Journal of Nuclear Medicine - doi: 10.2967/jnumed.121.263694 |
| Start Year | 2022 |
| Description | Collaboration with Life Molecular Imaging & ACI Immune on FTD |
| Organisation | Life Molecular Imaging |
| Country | Germany |
| Sector | Private |
| PI Contribution | Expertise in PET Imaging of neurodegenerative disease. |
| Collaborator Contribution | PET imaging of genetic FTD - 200,000 cases |
| Impact | In progress |
| Start Year | 2022 |
| Description | Collaboration with Ludwig Maximillian University |
| Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
| Department | University Clinic of Munich |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Overlap with group research interests and activiity. Collaboration focuses on ageing and dementia. |
| Collaborator Contribution | Academic expertise. |
| Impact | In progress. |
| Start Year | 2022 |
| Description | Dr M Malpetti Bye-Fellow at Sidney Sussex College, University of Cambridge |
| Organisation | University of Cambridge |
| Department | Sidney Sussex College, Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Promotion to bye-fellow |
| Collaborator Contribution | Promotion to bye-fellow |
| Impact | Promotion to bye-fellow |
| Start Year | 2024 |
| Description | Dr Maura Malpetti (Rowe Group) Collaboration with McGill University |
| Organisation | McGill University |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | • Collaboration with Dr. Matthias Brendel at the Ludwig Maximilian University of Munich (Germany) and Prof. Pedro Rosa-Neto at the McGill University (Canada) on the project "TSPO PET in tauopathies" |
| Collaborator Contribution | • Collaboration with Dr. Matthias Brendel at the Ludwig Maximilian University of Munich (Germany) and Prof. Pedro Rosa-Neto at the McGill University (Canada) on the project "TSPO PET in tauopathies" |
| Impact | • Collaboration with Dr. Matthias Brendel at the Ludwig Maximilian University of Munich (Germany) and Prof. Pedro Rosa-Neto at the McGill University (Canada) on the project "TSPO PET in tauopathies" |
| Start Year | 2025 |
| Description | Dr Maura Malpetti (Rowe Group) Collaboration with Prof Gabor Kovacs at the University of Toronto |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | • Collaboration with Prof Gabor Kovacs at the University of Toronto (Canada): "RT-Quick in PSP" |
| Collaborator Contribution | • Collaboration with Prof Gabor Kovacs at the University of Toronto (Canada): "RT-Quick in PSP" |
| Impact | • Collaboration with Prof Gabor Kovacs at the University of Toronto (Canada): "RT-Quick in PSP" |
| Start Year | 2025 |
| Description | Dr Maura Malpetti (Rowe Group) Collaboration with Prof. Gil Rabinovici at the University of California San Francisco |
| Organisation | University of California, San Francisco |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | • Research visit (February-April 2025) and Collaboration with Prof Gil Rabinovici at the University of California San Francisco on multiple studies |
| Collaborator Contribution | • Research visit (February-April 2025) and Collaboration with Prof Gil Rabinovici at the University of California San Francisco on multiple studies |
| Impact | • Research visit (February-April 2025) and Collaboration with Prof Gil Rabinovici at the University of California San Francisco on multiple studies |
| Start Year | 2025 |
| Description | Dr Maura Malpetti (Rowe Group) Collaboration with University of Cardiff |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | • Collaboration with Prof Paul Morgan and Dr Wiola Zelek at the University of Cardiff (UK): "Complement assays in neurodegenerative diseases" |
| Collaborator Contribution | • Collaboration with Prof Paul Morgan and Dr Wiola Zelek at the University of Cardiff (UK): "Complement assays in neurodegenerative diseases" |
| Impact | • Collaboration with Prof Paul Morgan and Dr Wiola Zelek at the University of Cardiff (UK): "Complement assays in neurodegenerative diseases" |
| Start Year | 2025 |
| Description | Dr Maura Malpetti (Rowe Group) Collaboration with University of Gothenburg |
| Organisation | University of Gothenburg |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | • Collaboration with Dr Rik Ossenkoppele, VU University Medical Center Amsterdam & Lund University on projects with Tau PET in AD and non-AD |
| Collaborator Contribution | • Collaboration with Dr Rik Ossenkoppele, VU University Medical Center Amsterdam & Lund University on projects with Tau PET in AD and non-AD |
| Impact | • Collaboration with Dr Rik Ossenkoppele, VU University Medical Center Amsterdam & Lund University on projects with Tau PET in AD and non-AD |
| Start Year | 2024 |
| Description | Dr Maura Malpetti (Rowe Group) Collaboration with VU University Medical Center Amsterdam & Lund University |
| Organisation | VU University Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | • Collaboration with Dr Rik Ossenkoppele, VU University Medical Center Amsterdam & Lund University on projects with Tau PET in AD and non-AD |
| Collaborator Contribution | • Collaboration with Dr Rik Ossenkoppele, VU University Medical Center Amsterdam & Lund University on projects with Tau PET in AD and non-AD |
| Impact | • Collaboration with Dr Rik Ossenkoppele, VU University Medical Center Amsterdam & Lund University on projects with Tau PET in AD and non-AD |
| Start Year | 2025 |
| Description | Dr Maura Malpetti (Rowe Group) Collaboration with • Collaboration with Ludwig Maximilian University of Munich |
| Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | • Collaboration with Prof Matthias Brendel, Prof Gunther Hoglinger, and Dr Nicolai Franzmeier at the Ludwig Maximilian University of Munich (Germany) on multiple studies |
| Collaborator Contribution | • Collaboration with Prof Matthias Brendel, Prof Gunther Hoglinger, and Dr Nicolai Franzmeier at the Ludwig Maximilian University of Munich (Germany) on multiple studies |
| Impact | • Collaboration with Prof Matthias Brendel, Prof Gunther Hoglinger, and Dr Nicolai Franzmeier at the Ludwig Maximilian University of Munich (Germany) on multiple studies |
| Start Year | 2025 |
| Description | ENIGMA MEG working group |
| Organisation | University of Southern California |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Supply of a dementia and healthy participants dataset. |
| Collaborator Contribution | TBC |
| Impact | A new collaboration in development, initiated late 2020 and the first meeting took place in January 2021. |
| Start Year | 2021 |
| Description | HKU AI partnership |
| Organisation | University of Hong Kong |
| Country | Hong Kong |
| Sector | Academic/University |
| PI Contribution | A new Cambridge UK to HKU partnership for to develop Artificial Intelligence for Social Good, in biomedicine |
| Collaborator Contribution | Establishing the partnership, developing research strategy, and funding applications, from private and statutory bodies |
| Impact | Pending |
| Start Year | 2022 |
| Description | Hosted Visiting Researcher (University of Cambridge)- Ivana Kancheva |
| Organisation | Utrecht University |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Tsvetanov KA took a lead in the training and supervision of this student. |
| Collaborator Contribution | Ivana Kancheva from Utrecht University hosted at the University of Cambiridge for 10 months in 2022 |
| Impact | Student training and ongoing analytical collaboration. |
| Start Year | 2022 |
| Description | MINDMAPS AD UK |
| Organisation | MRC Dementias Platform UK |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are collaborating with Imperial on the Mindmaps project, to combine their UCBJ PET data with our MEG data. The aim is to test the link between synaptic density changes and resting state connectivity in Alzheimer's disease. |
| Collaborator Contribution | Dr Eugenii Rabiner of Invicro, leads MIND MAPS - a collaboration between Invicro, the world's leading neuroscience translational imaging centre, six industry partners (AbbVie, Biogen, Celgene, Hamamatsu Photonics, Pfizer and Takeda) and UK's leading academic centres (King's College, Imperial College, University College, Cambridge, Newcastle). Each partner has contributed their particular expert knowledge. Invicro provided the overall scientific design and cutting edge imaging methodologies, the academic partners contribute disease specific knowledge and expertise in patient selection and care. Industry partners provide the knowledge of promising treatment targets and treatments. The collaboration combines these ingredients to ensure that the techniques being developed and tested by the team are truly fit for purpose to support future disease modifying clinical trials. It demonstrates a collaborative way of working that signposts the future of dementia research. |
| Impact | TBC |
| Start Year | 2017 |
| Description | NIHR BRC |
| Organisation | National Institute for Health Research |
| Department | NIHR Cambridge Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Biomarker development, including cognitive and imaging based deep phenotyping; |
| Collaborator Contribution | Cellular, physiological, radio-chemistry, genetic and pharmaceutical innovations within a pipeline for novel drug discovery; |
| Impact | Adams, N. E., Hughes, L. E., Phillips, H. N., Shaw, A. D., Murley, A. G., Nesbit, D., Cope, T. E., Bevan-Jones, W. R., Passamonti, L., Rowe, J. B. (2020). GABA-ergic dynamics in human frontotemporal networks confirmed by pharmaco magnetoencephalography, Journal of Neuroscience, https://doi.org/10.1523/JNEUROSCI.1689-19.2019. Lewis-Smith, D. J., Wolpe, N., Ghosh, B. C. P., Rowe, J. B. (2020). Alien limb in the corticobasal syndrome: phenomenological characteristics and relationship to apraxia, Journal of Neurology, https://doi.org/10.1007/s00415-019-09672-8. Jabbari, E., Chelban, V., Holland, N., Jones, P. S., Lamb, R., Rawlinson, C., Guo, T., Costantini, A. A., Tan, M. M. X., Heslegrave, A. J., Roncaroli, F., Klein, j. C., Ansorge, O., Allinson, K. S. J., Jaunmuktane, Z., Holton, J. L., Revesz, T., Warner, T. T., Lees, A. J., Zetterberg, H., Russell, L. L., Bocchetta, M., Rohrer, J. D., Williams, N. M., Grosset, D. G., Burn, D. J., Pavese, N., Gerhard, A., Kobylecki, C., Leigh, P. G., Church, A., Hu, M. T. M., Woodside, J., Houlden, H., Rowe, J. B., Morris, H. R. (2020). Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome, JAMA Neurology, doi:10.1001/jamaneurol.2019.4347. van der Ende, E. L,, Meeter, L. H., Poos, J. M., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., Papma, J. M., de Jong, F. J., Verberk, I., Teunissen, C. E., Rizopoulos, D., Heller, C., Convery, R. S., Moore, K. M., Bocchetta, M., Neason, M., Cash, D. M., Borroni, B., Galimberti, D., Sanchez-Valle, R., Laforce, Jr R., Moreno, F., Synofzik, M., Graff, C., Masellis, M., Tartaglia, M. C., Rowe, J. B., Vandenberghe, R., Finger, E., Tagliavini, F., de Mendonça, A., Santana, I., Butler, C., Ducharme, S., Gerhard, A., Danek, A., Levin, J., Otto, M., Frisoni, G. B., Cappa, S., Pijnenburg, Y. A. L., on behalf of the GENetic Frontotemporal Dementia Initiative (GENFI), Rohrer, J. D., van Swieten, J. C. (2019). Longitudinal serum neurofilament light chain in genetic frontotemporal dementia: a multicentre cohort study. Lancet Neurology, 18: 1103-1111, https://doi.org/10.1016/S1474-4422(19)30354-0. Shafto, M. A., Henson, R. N., Matthews, F. E., Taylor, J. R., Emery, T., Erzinclioglu, S., Hanley, C., Rowe, J. B., Cusack, R., Calder, A. J., Marslen-Wilson, W. D., Duncan, J., Dalgleish, T., Brayne, C., Cam-CAN, Tyler, L. K. (2019). Cognitive Diversity in a Healthy Aging Cohort: Cross-Domain Cognition in the Cam-CAN Project, Journal of Aging and Health, doi: 10.1177/0898264319878095 [ahead of print], PMID: 31592706 Lansdall, C. J., Coyle-Gilchrist, I. T. S., Vázquez Rodríguez, P., Wilcox, A., Wehmann, E., Robbins, T. W., Rowe, J. B. (2019). Prognostic importance of apathy in syndromes associated with Frontotemporal lobar Degeneration, Neurology, 92(14):e1547-e1557. doi: 10.1212/WNL.0000000000007249, PMID: 30842292, PMC: 6448451. Borchert, B. J., Rittman, T., Rae, C. L., Passamonti, L., Jones, P. S., Vatansever, D., Vazquez-Rodriguez, P., Ye, Z., Nombela, C., Hughes, L. E., Robbins, T. W., Rowe, J. B. (2019). Atomoxetine and citalopram alter brain network organization in Parkinson's disease, Brain Communications, 1:1 fcz013, https://doi.org/10.1093/braincomms/fcz013. PMID: [pending], PMC: [pending]. Nicastro, N., Surendranathan, A., Mak, E., Rowe, J. B.*, O'Brien, J. T.* (2019). 11C-PK11195 PET imaging and white matter changes in Parkinson's disease dementia, Annals of Clinical and Translational Neurology, doi: 10.1002/acn3.50877, PMID: 31507085, PMC: [pending]. Low, A., Mak, E., Malpetti, M., Chouliaras, L., Nicastro, N., Su, L., Holland, N., Rittman, T., Vázquez Rodríguez, P., Passamonti, L., Bevan-Jones, W. R., Jones, P. S., Rowe, J. B.*, O'Brien, J. T.* (2019). Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloid-positive mild cognitive impairment is associated with key clinical features, Alzheimer's & Dementia: Diagnosis, Assessment, & Disease Monitoring, 11: 690-699, DOI: https://doi.org/10.1016/j.dadm.2019.08.001, PMID: 31667328, PMC: 6811895. Tavares, T. P., Mitchell, D. G. V., Coleman, K., Shoesmith, C., Bartha, R., Cash, D. M., Moore, K. M., van Swieten, J. C., Borroni, B., Galimberti, D., Tartaglia, M. C., Rowe, J. B., Graff, C., Tagliavini, F., Frisoni, G., Cappa, S., Laforce, R. Jr, de Mendonça, A., Sorbi, S., Wallstrom, G., Masellis, M., Rohrer, J. D., Finger, E. C., GENetic Frontotemporal Dementia Initiative (GENFI) (2019). Ventricular volume expansion in presymptomatic genetic frontotemporal dementia, Neurology, doi: 10.1212/WNL.0000000000008386, PMID: 31578297, PMC: [pending]. Passamonti, L., Tsvetanov, K. A., Jones, P. S., Bevan-Jones, W. R., Arnold, R., Borchert, R. J., Mak, E., Su, L., O'Brien, J. T.*, Rowe, J. B.* (2019). Neuroinflammation and functional connectivity in Alzheimer's disease: interactive influences on cognitive performance, Journal of Neuroscience, doi: 10.1523/JNEUROSCI.2574-18.2019. PMID: 31320450, PMC: 6733539. Jabbari, E., Woodside, J., Guo, T., Magdalinou, N. K., Chelban, V., Athauda, D., Lees, A. J., Foltynie, T., Houlden, H., Church, A., Hu, M. T., Rowe, J. B., Zetterberg, H., Morris, H. R. (2019). Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes, Journal of Neurology, Neurosurgery and Psychiatry, 90(7):768-773. doi: 10.1136/jnnp-2018-320151. PMID: 30867224, PMC: 6585258. Hughes, L. E., Henson, R. N., Pereda, E., Bruña, R., López-Sanz, D., Quinn, A. J., Woolrich, M. W., Nobre, A. C., Rowe, J. B., Maestú, F., BioFIND Working Group (2019). Biomagnetic biomarkers for dementia: A pilot multicentre study with a recommended methodological framework for magnetoencephalography, Alzheimers & Dementia (Amsterdam, Netherlands), 11:450-462. doi: 10.1016/j.dadm.2019.04.009. PMID: 31431918, PMC: 6579903. Shaw, A. D., Hughes, L. E., Moran, R., Coyle-Gilchrist, I., Rittman, T., Rowe, J. B. (2019). In Vivo Assay of Cortical Microcircuitry in Frontotemporal Dementia: A Platform for Experimental Medicine Studies. Cerebral Cortex. 2019. doi: 10.1093/cercor/bhz024. PMID: 31216360. van Eimeren, T., Antonini, A., Berg, D., Bohnen, N., Ceravolo, R., Drzezga, A., Höglinger, G. U., Higuchi, M., Lehericy, S., Lewis, S., Monchi, O., Nestor, P., Ondrus, M., Pavese, N., Peralta, M.C., Piccini, P., Pineda-Pardo, J. Á., Rektorová, I., Rodríguez-Oroz, M., Rominger, A., Seppi, K., Stoessl, A. J., Tessitore, A., Thobois, S., Kaasinen, V., Wenning, G., Siebner, H. R., Strafella, A. P., Rowe, J. B. (2019). Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers & Dementia (Amsterdam, Netherlands). 11:301-309. doi: 10.1016/j.dadm.2019.01.011. PMID: 30984816, PMC: 6446052. Rittman, T., Borchert, R., Jones, P. S., van Swieten, J., Borroni, B., Galimberti, D., Masellis, M., Tartaglia, M. C., Graff, C., Tagliavini, F., Frisoni, G. B., Laforce, R. Jr, Finger, E., Mendonça, A., Sorbi, S., Rohrer, J. D., Rowe, J. B., GENetic Frontotemporal Dementia Initiative (GENFI) (2019). Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia, Neurobioly of Aging, 77:169-177. doi: 10.1016/j.neurobiolaging.2018.12.009, PMID: 30831384; PMC: 6491498. Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T., Arnold, R., Coles, J. P., Aigbirhio, F. I., O'Brien, J. T., Rowe, J. B. (2019). In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier. Annals of Clinical Translational Neurology, 6(2):373-378. doi: 10.1002/acn3.683. PMID: 30847369; PMC: 6389753. |
| Start Year | 2017 |
| Description | NTAD Collaboration with UCL-UK DRI Plasma Tau Analysis |
| Organisation | UK Dementia Research Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | NTAD study provides blood samples obtained from participants with Alzheimer's disease. |
| Collaborator Contribution | Collaboration with Dr Henrik Zetterberg & Dr Amanda Heslegrave, UK DRI Fluid Biomarker Laboratory at UCL, for plasma tau analysis obtained from NTAD participants. |
| Impact | TBC |
| Start Year | 2020 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | Alzheimer's Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | AstraZeneca |
| Department | Astra Zeneca |
| Country | United States |
| Sector | Private |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | Eli Lilly & Company Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | Johnson & Johnson |
| Department | Janssen Pharmaceuticals |
| Country | United States |
| Sector | Private |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | PREVENT 7T |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Application of 7T technology to understand the effects of inherited risk of dementia |
| Collaborator Contribution | Coordination of national PREVENT study of people at risk of dementia |
| Impact | Pending |
| Start Year | 2019 |
| Description | Prof. James Rowe - Alector |
| Organisation | Alector |
| Country | United States |
| Sector | Private |
| PI Contribution | Advisory and research. |
| Collaborator Contribution | Advisory and research. |
| Impact | Advisory and research. |
| Start Year | 2024 |
| Description | Prof. James Rowe - Booster |
| Organisation | Boostec |
| Country | France |
| Sector | Private |
| PI Contribution | Advisory and research. |
| Collaborator Contribution | Advisory and research. |
| Impact | Advisory and research. |
| Start Year | 2024 |
| Description | Prof. James Rowe - Clinical Ink |
| Organisation | Irish Critical Care Clinical Trials Network |
| Country | Ireland |
| Sector | Hospitals |
| PI Contribution | Advisory and research. |
| Collaborator Contribution | Advisory and research. |
| Impact | Advisory and research. |
| Start Year | 2024 |
| Description | Prof. James Rowe - Ferrer |
| Organisation | Ferrer Internacional |
| Country | Spain |
| Sector | Private |
| PI Contribution | Advisory and research |
| Collaborator Contribution | Advisory and research |
| Impact | Ongoing |
| Start Year | 2024 |
| Description | SENDeR & TENDeR UCL/Oxford collaboration |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | All research activities take place in Cambridge as the Primary Research Site. |
| Collaborator Contribution | UCL and Oxford site have been added as Patient Identification Sites. |
| Impact | TBC |
| Start Year | 2020 |
| Description | SENDeR & TENDeR UCL/Oxford collaboration |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | All research activities take place in Cambridge as the Primary Research Site. |
| Collaborator Contribution | UCL and Oxford site have been added as Patient Identification Sites. |
| Impact | TBC |
| Start Year | 2020 |
| Description | Study Agreement with AC Immune on FTD Project |
| Organisation | AC Immune |
| Country | Switzerland |
| Sector | Private |
| PI Contribution | PI and Post0Doctoral Researcher will actively run the "Evaluation of PI-2620 PET in Familial Frontotemporal Dementia" study. |
| Collaborator Contribution | EUR 161000 in funding |
| Impact | Outcomes pending |
| Start Year | 2022 |
| Description | Supervisor with Caius Higher Aspiration Scheme - Rebecca Williams (Rowe Group) |
| Organisation | University of Cambridge |
| Department | Gonville and Caius College |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Supervisor to 6 students (Year 12) |
| Collaborator Contribution | Aspiration Scheme |
| Impact | Student development. |
| Start Year | 2022 |
| Description | UK7T Network |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | UK7T Network |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | UK7T Network |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | UK7T Network |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | UK7T Network |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | UK7T Network |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | Visiting Researcher at University of California San Francisco (US) - Dr Maura Malpetti |
| Organisation | University of California, San Francisco |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Visiting researcher at University of California San Francisco (US) |
| Collaborator Contribution | Visiting researcher at University of California San Francisco (US) |
| Impact | Visiting researcher at University of California San Francisco (US) |
| Start Year | 2025 |
| Title | Atomoxetine in PSP |
| Description | new drug strategy for impulsivity in PSP to be tested for first time. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2017 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | reduced impulsivity in selected patients |
| Title | Biomarker evaluation of 7T MRI in dementia |
| Description | evaluation of novel 7T MRI for early detection of pathology in AD, and other dementias, building on the JPND consortium "EUFIND" |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Impact | stronger links to basic cognitive neurosciences of memory systems, and to multi-centre clinical transnational centres across EU |
| Title | Non CTIMP for Memantine and Tiagabine |
| Description | Looking at modulating GABA and Glutamate in patients with Frontotemporal Lobar Degeneration via Magnetoencephalography and 7T MRS studies. ADD a bit more from the grant itself. |
| Type | Support Tool - For Medical Intervention |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Impact | You can link it in to the EXT DCM model of GABA and Gluatame as per Journal of Neurology publication by Tallie |
| Title | Tiagabine in FTLD |
| Description | New drug strategy for impulsivity in FTLD tested for first time. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2021 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Reduced impulsivity in selected patients. |
| Description | 'Sleep, Consciousness and Cognition' Dr Marlou Perquin (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | • Poster presentation at the Cambridge Neuroscience Seminar, Cambridge, CNS2024: 'Sleep, Consciousness and Cognition'. The target audience is local neuroscientists from any discipline as well as those interested specifically in the topic of consciousness. Audience size was ~250 delegates. Perquin, M.N., Daghlian, M., Perry, G., Singh, K., & Bompas, A. (2024). Predicting ongoing fluctuations in behavioural variability and subjective attentional state. Cambridge Neuroscience Seminar, Cambridge. |
| Year(s) Of Engagement Activity | 2024 |
| Description | All About Brians - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Virtual contribution at Storyhouse Theatre Chester, UK. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Alzheimer's Association International Conference - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "From glia to cytokine signatures across the Alzheimer's spectrum (and beyond)" - Alzheimer's Association International Conference (AAIC, Philadelphia, 31/07/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Article & Interview Neurodegenerative Disease and Dementia |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Damage to the brainstem - the brain's 'control centre' - is behind long-lasting physical and psychiatric effects of severe Covid-19 infection, a study suggests. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://cambridgebrc.nihr.ac.uk/tag/neurodegenerative-disease-and-dementia/ |
| Description | Ask a Dr Event - Dr Negin Holland (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Invited clinician at the PSP Association 'Ask the Dr event' - at least 3 times/year |
| Year(s) Of Engagement Activity | 2023 |
| Description | Astex Pharmaceuticals Seminar Cambridge - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Inflammation biomarkers in FTD and related disorders: from pathological pathways to clinical trials" - Astex Pharmaceuticals Seminar (Cambridge, 30/08/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | BBC Persian Interview on Dementia Research January 2024 - Dr Negin Holland & Prof. James B Rowe |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Interviewed by BBC Persian about Dementia research on 25th January 2024 |
| Year(s) Of Engagement Activity | 2024 |
| Description | BarcelonaBeta - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Brain inflammation in dementia: what can we learn from PET imaging and blood markers?" - BarcelonaBeta (Barcelona, 02/04/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Big Biology Day |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | The Big Biology Day at Hills Road Sixth Form College, Cambridge, is a science festival celebrating the life sciences through hands-on activities, crafts, and interactive displays. As a volunteer at the Alzheimer's Research UK stand, I helped educate children about brain health and dementia, contributing to the event's mission to engage people of all ages with science. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Big Biology Day - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Live at Hills Road Sixth Form, collaboration with ARUK |
| Year(s) Of Engagement Activity | 2022 |
| Description | Brain Bank Symposium |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Regional Brain Bank meeting, chair |
| Year(s) Of Engagement Activity | 2023 |
| Description | Brain Imaging A Short Taster - Psychi Summer Camp (Dr Laura Hughes - Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Undergraduate students |
| Results and Impact | Brain imaging - a short taster". Psychi Summer Camp, online, August 2024 Audience: Undergraduate Students |
| Year(s) Of Engagement Activity | 2024 |
| Description | Brain Models & Pipecleaner Neurons (Rebecca Williams - Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Collaboration with CHaOS - live at school in St. Neots, UK |
| Year(s) Of Engagement Activity | 2022 |
| Description | CBU Science Night - MEG Demo (Dr Marlou Perquin - Rowe Group) |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | • MEG demonstration at the CBU science night (public engagement). The target audience is laypeople with an interest in cognitive neuroscience research. Audience size for the MEG demonstrations was about 50 people in total. |
| Year(s) Of Engagement Activity | 2024 |
| Description | CHaOS Summer Roadshow (Rebecca Williams - Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Live at Poacher Scout's Jamboree (over 6000 in attendance) |
| Year(s) Of Engagement Activity | 2022 |
| Description | CUH Memory Clinic Annual Study and Review Day |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | CUH Memory clinic annual study and review day |
| Year(s) Of Engagement Activity | 2023 |
| Description | Cerevance Seminar Cambridge (Dr Maura Malpetti - Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Inflammation biomarkers in FTD and related disorders: from pathological pathways to clinical trials" - Cerevance Seminar (Cambridge, 29/01/2025) |
| Year(s) Of Engagement Activity | 2025 |
| Description | Chair at Tau 2024 International Conference |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Tau2024 Global Conference | March 25 - 26, 2024 | Washington, D.C., USA and Online 1 Leading tau experts from around the world representing academia, industry, government and the philanthropic sector will come together to collaborate and discuss key issues impacting the tau research community. Scientific Program Committee James Rowe, chair |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://istaart.alz.org/events/item/23/127 |
| Description | Collaboration with artist for Creative Reactions - Dr Marlou Perquin (Rowe Group) |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | • Collaboration with artist for Creative Reactions, which is a standalone part of Pints of Science. Part of the scientific speakers are paired up with a local artist who makes an art work inspired by the researcher's topic. Emily Jolley from Emily Jolley Fine Art created two paintings based on the topic of intra-individual variability and dementia. Over and over, Emulsion paint and graphite on board Until it's over, Emulsion paint and graphite on board |
| Year(s) Of Engagement Activity | 2024 |
| Description | Coordinator FTDUK Conference |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | FTDUK - coordinator and talk London |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.ftduk.org/previous-programmes/#1684055574796-923f2281-2b7e |
| Description | Coping with Exam Stress - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | In collaboration with Study Together |
| Year(s) Of Engagement Activity | 2022 |
| Description | Dementia Champions link Day - Dr Anna Dreyer (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Staff from a variety of in-patient clinical areas attended Dementia Champion link day at Hinchingbrooke Hospital (25 March 2024) and Peterborough City Hospital (24 June 2024) where I did presentations on dementia research |
| Year(s) Of Engagement Activity | 2024 |
| Description | Dementia Chatathon - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Collaboration with Dementia Researcher, watched via Youtube, Twiter & Twitch |
| Year(s) Of Engagement Activity | 2022 |
| Description | Dementia Researcher Podcasts and Fundraising events - Dr M Malpetti |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | https://www.dementiaresearcher.nihr.ac.uk/tag/dr-maura-malpetti/ |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.dementiaresearcher.nihr.ac.uk/tag/dr-maura-malpetti/ |
| Description | Dr Amirhossein Jafarian - Media interview (Rowe Group) |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | See interview. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.dementiasplatform.uk/about-us/teams-and-people/amirhossein-jafarian-1 |
| Description | Dr Anna J Dreyer (Rowe Group) Invited Speaker Tau 2025 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dissemination of the findings of this project at Tau 2025 in London, UK |
| Year(s) Of Engagement Activity | 2025 |
| Description | Dr M Malpetti Invited career panel speaker at the Biomarker UCL course for PhD students |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Invited career panel speaker at the Biomarker UCL course for PhD students (London, 18/05/2022) |
| Year(s) Of Engagement Activity | 2022 |
| Description | Dr M Malpetti Speaker at Cambridge Alumni Festival |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | • Speaker at Cambridge Alumni Festival public talk: "Brain inflammation in the race against dementia" (~150 attendees, Cambridge 28/09/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Dr M Malpetti Speaker at TEDxMantova Talk |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Mantua |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.ted.com/tedx/events/57098 |
| Description | Dr M Malpetti Speaker at the ARUK Public webinar |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr M Malpetti Speaker at the ARUK Public webinar |
| Year(s) Of Engagement Activity | 2025 |
| Description | Dr M Malpetti • Speaker at the PSPA research day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | • Speaker at the PSPA research day: "Brain scans and blood tests to track inflammation (~70 attendees, virtual, 23/05/2024) |
| Year(s) Of Engagement Activity | 2025 |
| Description | Dr M Malpetti • Speaker at the Race Against Dementia |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | • Speaker at the Race Against Dementia summit "Where dementia research meets F1 mentality" (~100 attendees, 11/09/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Dr Maura Malpetti (Rowe Group): Oral Presentation at DPUK Translation 2023 Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation on "Post mortem validation of in vivo PET imaging: test case of inflammation in progressive supranuclear palsy" |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.dementiasplatform.uk/research-hub/translation-2023/early-career-researchers-workshop-and... |
| Description | Dr Maura Malpetti PSPA (Progressive Supranuclear Palsy Association) research committee member |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Committee member |
| Year(s) Of Engagement Activity | 2024 |
| Description | Dr Maura Malpetti Tau2025 Conference Organising committee |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Organizer |
| Year(s) Of Engagement Activity | 2024 |
| Description | ECR Talk Translation 2024 DPUK (Dr Amirhossein Jafarian - Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Translation 2024 DPUK 2024 (ECR talk and Poster presentation) |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.youtube.com/watch?v=J8cTqeUoiPw |
| Description | Effective Note Taking Strategies: Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | Collaboration with Study Together |
| Year(s) Of Engagement Activity | 2022 |
| Description | EuroWeekly News |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | A trial hailed as the "holy grail" by experts, conducted by the NHS, is in its first stages this week, with 3,100 participants worried they are showing signs of possible dementia, such as memory loss, to have their blood tested and get a speedy diagnosis. |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://euroweeklynews.com/2025/01/29/holy-grail-revolutionary-new-blood-test-to-diagnose-dementia-u... |
| Description | European Meeting on Imaging of Neurodegenerative Diseases (EU-MIND) - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "PET imaging of synaptic health across neurodegenerative diseases" - European Meeting on Imaging of Neurodegenerative Diseases (EU-MIND, Caen, 26/09/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Experimental Medicine in FTD |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk ISFTD meeting Amsterdam n=700 "Experimental medicine in FTD" |
| Year(s) Of Engagement Activity | 2024 |
| Description | FTD Holloway Summit (Miama, USA) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | State of science and clinical epidemiology of FTD. |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://www.theaftd.org/fr/holloway-summit-2025/ |
| Description | Filmed Charity Broadcast for PSP Association |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | PSPA broadcast. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Greatest Hits Oxfordshire - Hello Rayo! |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Oxford university in trials for blood tests to diagnose dementia A multi-million pound programme is supported by the Alzheimer's Society |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://hellorayo.co.uk/greatest-hits/oxfordshire/news/oxford-university-in-trials-for-blood-tests-t... |
| Description | How to Tackle an Academic Paper - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | How to Tackle an Academic Paper |
| Year(s) Of Engagement Activity | 2022 |
| Description | How to tackle Academic Teading and Writing - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Summer CAMP collaboration. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Human Amyloid Imaging 2025 - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Novel blood-based proteomic signatures for multiple neurodegenerative diseases" - Human Amyloid Imaging 2025 (Puerto Rico, 17/01/2025) |
| Year(s) Of Engagement Activity | 2025 |
| Description | ISTAART FTD PIA symposium - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Fluid markers of inflammation in FTLD" - ISTAART FTD PIA symposium (Virtual, 24/04/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | In Conversation at Christmas - Broadcast on Dementia |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | In conversation at Christmas is a stimulating discussion, covering some of the progress made in research in 2022, and looking ahead to 2023. Hear from our Chief Scientific Officer, Prof James Rowe and Head of Research, Dr Rosa Sancho and ambassador for Alzheimer's Research UK, Scott Mitchell. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.youtube.com/watch?v=Vwp8QNIJSZ4 |
| Description | International Society of Frontotemporal Dementia Conference - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Blood-based inflammation markers predict survival in syndromes associated with FTLD" - International Society of Frontotemporal Dementia Conference (Amsterdam, 22/09/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Interventional Studies - Cinical Research Training Day (Dr Laura Hughes - Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Interventional Studies" Clinical training day at HSB, in person. August 2024 Audience: New staff and students at HSB. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Investigating Blood-Based Biomarkers With Dr. Maura Malpetti |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | DESCRIPTION Clinical trials are urgently needed for PSP and CBD. Dr. Maura Malpetti and her team at the University of Cambridge have identified chronic brain inflammation as a key contributor to disease progression, and are developing a blood test for inflammation that will help track the effectiveness of clinical trials and treatments, thus accelerating the development of more clinical trials. |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://www.psp.org/podcast/episode/maura-pod |
| Description | Invited Lecturer at Statistical Parametric Mapping Course, London - Dr A Jafarian (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dynamic causal modelling |
| Year(s) Of Engagement Activity | 2023 |
| Description | Lecture to MPhil Students in Basic and Translational Neuroscience - Dr M Malpetti |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Lecture on the MPhil in Basic and Translational Neuroscience, University of Cambridge (Cambridge, 24/10/2022): "Dementia and neurodegenerative diseases: what have we learned from brain imaging?" |
| Year(s) Of Engagement Activity | 2022 |
| Description | Let's Talk Science - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Skyped in to Birmingham, USA |
| Year(s) Of Engagement Activity | 2022 |
| Description | Let's Talk Science! Skype a Scientist, Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | Engagement via Skype a Scientist to Missouri, USA. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Lundbeck Foundation Neuroscience Network |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk - Lundbeck Foundation Neuroscience Network Copenhagen "Synaptic Health" |
| Year(s) Of Engagement Activity | 2024 |
| Description | MEG as a Platform for Clinical Trials - MEGIN Pharmaco Symposium (Dr Laura Hughes - Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "MEG as a platform for clinical trials. From understanding disease to supporting experimental medicine" MEGIN Pharmaco Symposium, Geneva, 8th April 2024 |
| Year(s) Of Engagement Activity | 2024 |
| Description | MEG as a platform for clinical trials - Dr Laura Hughes (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "MEG as a platform for clinical trials. From understanding disease to supporting experimental medicine" Joint Spring symposium Clinical Neurophysiology & Belgian Neurological Society, Brussels, 16th March 2024 o Audience: ~150 people, audience is academic staff and student members of the Belgium societies. |
| Year(s) Of Engagement Activity | 2024 |
| Description | MEGIN - MEG in Pharmaco Meeting, Geneva - Prof James B Rowe |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | MEGIN - MEG in pharmaco meeting, Geneva, 8th April 2024 "MEG biomarkers for Alzheimer's disease, mechanisms and progression" Symposium with academic and industry partners N~100 |
| Year(s) Of Engagement Activity | 2024 |
| Description | MSN News |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Simple dementia-detecting blood test begins NHS trial |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://www.msn.com/en-gb/health/other/simple-dementia-detecting-blood-test-begins-nhs-trial/ar-AA1y... |
| Description | Magnetoencephalography versus blood-based biomarkers of Alzheimer's Disease (Dr Marlou Perquin - Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation plus 3-minute oral presentation at MEG UK, Birmingham. The target audience is MEG researchers in the UK. Audience size was ~200 delegates. Perquin, M.N., Lanskey, J.H., Karadag, M., Kocagoncu, E., Quinn, A.J., Pitt, J., van Es, M., Alcock, C., Shen, C., Krugliak, A., Thayanandan, T., Fye, H., Lowe, S., Perkinton, M., Timmers, M., Raymont, V., Singh, K.D., Woolrich, M., Nobre, A.C., Rowe, J.B., the NTAD group. Magnetoencephalography versus blood-based biomarkers of Alzheimer's Disease. MEG UK, Birmingham. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Media Coverage - The Mirror (Prof James B Rowe) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Media interview |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://www.mirror.co.uk/news/health/i-think-ive-alzheimers-havent-34573468 |
| Description | Media Coverage - The Sun (Prof James B Rowe) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | GAME CHANGER Simple blood test that could detect dementia 'YEARS before symptoms begin' starts 'exciting' trial in NHS clinics |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://www.thesun.co.uk/health/33070031/blood-test-dementia-symptoms-nhs-clinics-cheap/ |
| Description | Meeting and Workshop Innsbruck |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | LC Meeting |
| Year(s) Of Engagement Activity | 2024 |
| Description | Milton Keynes FM |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Simple blood test for dementia. |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://www.mkfm.com/news/technology/simple-blood-test-that-could-detect-dementia-at-early-stage-beg... |
| Description | Mini Linguistic State Examination (MLSE) Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Presentation at Mini Linguistic State Examination (MLSE) workshop |
| Year(s) Of Engagement Activity | 2023 |
| Description | Mirror Article on Corticobasal Degeneration feat. Prof James B Rowe |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Retired teacher who walks to slow down her dementia eyes trek round coast of Wales.. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.mirror.co.uk/news/health/retired-teacher-who-walks-slow-29620344 |
| Description | NULISA Multi-plex Panels in Dementia - UKDRI Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "NULISA multi-plex panels in dementia" - UKDRI Alamar Oxford Seminar (Oxford, 05/02/2025) |
| Year(s) Of Engagement Activity | 2025 |
| Description | Neuro2024 (PSP/CBS symposium) - Dr Negin Holland (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral Presentation: Neuro2024 (PSP/CBS symposium) - October 2023; attendees over 400 Title: Title: Differential patterns of in vivo synaptic loss in relation to tau accumulation and grey matter atrophy, in amyloid negative vs. positive corticobasal syndrome. Poster Presentation Award received. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Neuro2024 CurePSP symposium - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Beyond tau: PET imaging of inflammation and synapses in PSP/CBD" - Neuro2024 CurePSP symposium (Toronto, 24/10/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Neuroinflammation in Neurodegeneration Symposium CAMBRIDGE - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Inflammation fingerprints in dementia: from brain imaging to blood tests" - Neuroinflammation in Neurodegeneration Symposium (Cambridge, 17/04/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Neuroscience Academy Denmark Annual Symposium - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | "Present and future of PET imaging in frontotemporal dementia and related disorders" - Neuroscience Academy Denmark Annual Symposium (Copenhagen, 29/10/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | News Coverage - This is the Coast Radio |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | This is the coast |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://www.thisisthecoast.co.uk/news/video/simple-blood-test-that-could-detect-dementia-at-early-st... |
| Description | News coverage of finding that 7T MRI predicts new drug response in Parkinsons disease |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Report on finding that ultra-powerful brain scanners could offer hope for the treatment of previously-untreatable symptoms in Parkinson's disease, a new study suggests. See links below: https://www.independent.co.uk/news/health/patients-cognition-university-of-cambridge-b2080470.html https://www.upi.com/Health_News/2022/05/16/7T-MRI-Parkinsons-study/9901652724269/ https://www.thetimes.co.uk/article/advanced-7t-mri-scanner-could-benefit-parkinsons-patients-fcqqp2797 https://healthcare-in-europe.com/en/news/7t-brain-scanners-parkinson-s-disease.html https://www.cambridgeindependent.co.uk/news/high-powered-mri-scanners-could-identify-parkinson-s-patient-9254685/ |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.itv.com/news/anglia/2022-05-17/new-scanners-offer-hope-for-treating-parkinsons-disease |
| Description | Oral Presentation - Dr K Stockton "Metabolomic effects of sporadic, genetic and pre-symptomatic frontotemporal dementia" |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Metabolomic effects of sporadic, genetic and pre-symptomatic frontotemporal dementia. GENFI winter meeting International meeting of research study |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oral Presentation @ ADPD Barcelona 20222- Dr M Malpetti |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | "In vivo PET imaging of inflammation as a prognostic tool in frontotemporal dementia" - ADPD conference (Barcelona, 03/2022) |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oral Presentation Dr D Street at Midlands Neurological Society Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation Non-motor markers predict survival in PSP |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oral Presentation Dr M Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Undergraduate students |
| Results and Impact | • "Novel PET Tracers for Dementia" - SINdem4Juniors: 11th Winter Seminar on Dementia and Neurodegenerative Disorders (Brixen, 16/02/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Oral Presentation Dr M Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | • "Brain inflammation in dementia: what can we learn from PET imaging and blood markers?" - CUBRIC Seminar Series at the Cardiff University Brain Imaging Center (Cardiff, 09/10/2023) |
| Year(s) Of Engagement Activity | 2023 |
| Description | Oral Presentation Dr M Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Synaptic biomarkers in FTD: PET imaging in sporadic cases" - Frontotemporal Dementia UK meeting (London, UK, 12/05/2023) |
| Year(s) Of Engagement Activity | 2023 |
| Description | Oral Presentation Dr M Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Post mortem validation of in vivo PET imaging: test case of inflammation in progressive supranuclear palsy" - Dementias Platform UK Translation 2023 meeting (London, UK - 03/2023) |
| Year(s) Of Engagement Activity | 2023 |
| Description | Oral Presentation Dr M Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Serum cytokines across dementias: fingerprinting inflammation" - Alzheimer's & Parkinson's Diseases Conference (Gothenburg, 03/2023) |
| Year(s) Of Engagement Activity | 2023 |
| Description | Oral Presentation Dr M Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Inflammation markers in prodrome and prediction of dementia" - Interdisciplinary Dementia and Aging Centre (iDEAC) at University Hospital Southampton NHS Foundation Trust (Southampton, UK, 23/05/2023) |
| Year(s) Of Engagement Activity | 2023 |
| Description | Oral Presentation Dr M Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "From brain scans to blood tests - multidisciplinary progress on inflammation in dementia" - Cambridge Neuroscience Symposium 2023 (Cambridge, 26/09/2023) |
| Year(s) Of Engagement Activity | 2023 |
| Description | Oral Presentation Dr M Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Inflammation in dementia: a target for new treatments?" - NIAS Expert Workshop For Women in Science 2023 (Amsterdam, 13/07/2023) |
| Year(s) Of Engagement Activity | 2023 |
| Description | Oral Presentation Dr M Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Peripheral and central markers of inflammation in frontotemporal dementia and related conditions" - Frontotemporal Dementia UK meeting (London, UK, 12/05/2023) |
| Year(s) Of Engagement Activity | 2023 |
| Description | Oral Presentation: Caius Higher Aspiration Scheme - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Caius Higher Aspiration Scheme |
| Year(s) Of Engagement Activity | 2023 |
| Description | Oral Presentation: Translational neuropsychiatry @ BIOMAG 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk title "Translational neuropsychiatry" |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oxford Autumn School of Neuroscience - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Undergraduate students |
| Results and Impact | • "Inflammation in neurodegeneration: a key player in movement disorders and dementia" -Oxford Autumn School of Neuroscience (Oxford, 08/10/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | PPIE Dementia Group Event at Peckover House, Wisbech (Rowe Group) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Peckover House, Wisbech Lucy Bowns, Dr Maura Malpetti, Rebecca Williams Observations/thoughts/comments • Peckover House has been given funding to provide this dementia group. Currently it is the only National Trust property to offer this. It is hoped that it might expand to another five sites, pending ongoing funding. |
| Year(s) Of Engagement Activity | 2023 |
| Description | PSP pathogenesis - Bispebjerg Hospital Copenhagen |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation |
| Year(s) Of Engagement Activity | 2024 |
| Description | PSPA Research Day - Oral Presentation Dr K Stockton |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | "Pick's disease and Progressive supranuclear palsy Prevalence and Incidence study (PiPPIN)" 3/2/23 PSPA Research Day Research day for patients and carers, organised by the PSP association |
| Year(s) Of Engagement Activity | 2022 |
| Description | Pint of Science: Atoms to Galaxies |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Events held live in Cambridge UK |
| Year(s) Of Engagement Activity | 2022 |
| Description | Poster Presentation Association of British Neurologists - Dr K Stockton |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation titled: Pick's disease and Progressive supranuclear palsy Prevalence and Incidence study (PiPPIN) |
| Year(s) Of Engagement Activity | 2022 |
| Description | Poster Presentation International Society for FTD - Dr K Stockton |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | "Metabolomic effects of sporadic, genetic and pre-symptomatic frontotemporal dementia". France |
| Year(s) Of Engagement Activity | 2022 |
| Description | Poster Presentation: Clinical Neurosciences Day, Cambridge University - Dr K Stockton |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster on "Metabolomic effects of sporadic, genetic and pre-symptomatic frontotemporal dementia". With poster blitz presentation. In person, UK |
| Year(s) Of Engagement Activity | 2022 |
| Description | Psychiatry Meeting on Drug Treatments in Old Age |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk title "Frontotemporal Dementia" |
| Year(s) Of Engagement Activity | 2023 |
| Description | Public Meeting on Memory - Cambridge Festival |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | In My Memory Clinic and Me (31 March, 4-5.30pm), three internationally renowned experts in the field of dementia research and consultant neurologists at The Cambridge Memory Clinic, Professor James Rowe, Dr Timothy Rittman and Dr Andrew Graham, explain what dementia is and how it affects the brain. They discuss who gets referred to a memory clinic and the path to diagnosis, what happens once a person has been diagnosed, and how attending clinic can help with understanding the diagnosis and obtaining support through, for instance, a specialist dementia nurse. Moreover, they describe the role of the memory clinic in groundbreaking research, how the collaboration between hospitals and academic institutions makes vital research possible, and how this relates to patient care. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.festival.cam.ac.uk/news/press-release-leading-experts-discuss-mental-health-cambridge-fe... |
| Description | Rebecca Williams - A Career in Science |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | Virtual careers session for ~12000 12-18-year-olds in greater New York (TBD March 3rd) |
| Year(s) Of Engagement Activity | 2025 |
| Description | Rebecca Williams - Apathy in Dementia |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | University of the Third Age |
| Year(s) Of Engagement Activity | 2025 |
| Description | Rebecca Williams - Gonville & Cauis |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Given multiple times to Y9-11 students as part of an academic taster on their outreach programme (>200 students). |
| Year(s) Of Engagement Activity | 2024 |
| Description | Rebecca Williams - I'm a Scientist (and so are you) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | ~120 primary children (age 7-12) from an area of high depravation. |
| Year(s) Of Engagement Activity | 2024 |
| Description | Rebecca Williams - MEGUK |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Living in a World of "Close Enough": Apathy and the Bayesian Brain |
| Year(s) Of Engagement Activity | 2024 |
| Description | Rebecca Williams - Motivation & Dementia |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | CBU Cambridge |
| Year(s) Of Engagement Activity | 2024 |
| Description | Rebecca Williams - Science Communication |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Cambridge Neuroscience |
| Year(s) Of Engagement Activity | 2024 |
| Description | Rebecca Williams - Skype a Scientist Participant |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | Lets talk science |
| Year(s) Of Engagement Activity | 2024 |
| Description | Regular Blogger with Dementia Research - Rebecca Williams |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Hello! My name's Rebecca and I'm a second-year PhD student at the University of Cambridge. Though originally from 'up North' in a small town called Leigh, I did my undergraduate and masters at the University of Oxford before defecting/seeing the light (depends who you ask) to Cambridge for my doctorate. I now spend the majority of my days collecting data from our wonderful volunteers, and coding. I maintain that after spending entire days coding analysis pipelines I am very close to actually being able to see the matrix. In my spare time, I am a big fan of crafting in all its forms, and recently got a sewing machine to start designing my own clothes! I also greatly enjoy playing board games, and escape rooms. |
| Year(s) Of Engagement Activity | 2024,2025 |
| URL | https://www.dementiaresearcher.nihr.ac.uk/author/rebecca-williamsmrc-cbu-cam-ac-uk/ |
| Description | SPM for M/EEG course London (Dr Amirhossein Jafarian - Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Principles of Dynamic Causal Modelling (DCM) | Dr Amirhossein Jafarian | SPM for EEG and MEG |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.youtube.com/watch?v=tD9peFEq1KQ |
| Description | Scientific Programme Chair: Tau2024 Global Conference Prof. James B Rowe |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Served as programme chair. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://istaart.alz.org/events/item/23/127 |
| Description | Scottish Dementia Conference - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | ON-FIRE: a UK-wide study on inflammation in frontotemporal dementia" - Scottish Dementia Conference (Dundee, 14/06/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Session Chair - DPUK Translations 2024 - The Use of Biomarkers in Experimental Medicine |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dementia Platform UK has an annual conference which explores the issues and discoveries emerging in Translational Research for dementia. They bring together people who are working within this vital area of in-human rsearch. Each conference has sessions on trials delivery, working with large data and experimental medicine. All these are crucial to making the discoveries which will deliver the therapeutics and new drugs quickly and at a large scale. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.youtube.com/watch?v=i_Wl7I-WPrQ&list=PLhC6xt3e_5jsuaZvIo5pvSlb19ODAq9hD&index=1 |
| Description | Session Chair-The future of research on the risk factors of FTD |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | On behalf of the Board of Directors and AFTD staff, thank you for attending the Holloway Summit 2025. Over the next two days, you and other brilliant researchers on FTD will talk about the risk factors of FTD - what we know about them today and what we hope to learn tomorrow. The more we understand the causes of FTD, the most likely we are to see future cases reduced to a small number. It can happen, and it can happen in the course of our lives. If you have a previous Holloway Summit, you know that this cause is close to my heart. My husband, Lee Holloway, was diagnosed with FTD in 2017. Lee and I met we when were both working at Cloudflare, the Internet security company that he had co-founded. I was working in communications, while Lee was -- as aFILARYmagazine profile described -- "The resident genius of Cloudflare, the guy who could concentrate for hours, the code slipping at his fingertips. Thanks to Lee's genius, Cloudflare has become possible the most trusted name in the world in terms of cybersecurity. Like so many who others love someone with DFT, I have spent a lot of time and energy ending this disease, both by funding crucial research on DFT and by facilitating groundbreaking discussions among opinion leaders in the field of neurodegeneration. I have seen with my own eyes that we are closer than ever to leave our mark on the science of FTD and that viable treats are on the horizon. Of course, these treatments can only become a reality through collaboration, innovation, and hard, unspeakable scientific work - in short, the work you do every day. Thank you all, once again, for being here. I am proud to support the Holloway Summit since its launch in 2022. And I know that together we are opening the way to a future without FTD. |
| Year(s) Of Engagement Activity | 2025 |
| URL | https://www.theaftd.org/fr/holloway-summit-2025/ |
| Description | Sutton Trust MEG Talks - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Undergraduate students |
| Results and Impact | Event held at the MRC Cognition Brain Unit |
| Year(s) Of Engagement Activity | 2022 |
| Description | Synaptic Health in Dementia (German Society for Neurology) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | German Society for Neurology |
| Year(s) Of Engagement Activity | 2024 |
| Description | Tactile sensorimotor transformations are reliable over time, but do not generalise across tasks. (Dr Marlou Perquin - Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • Oral talk at the Annual Meeting of the Society for Mathematical Psychology in Tilburg, the Netherlands. The target audience of MathPsych is those interested in mathematical and computational theories of human cognition. Audience size was around 200-400 delegates. Perquin, M.N., Kayser, C., & Heed, T. (2024). Tactile sensorimotor transformations are reliable over time, but do not generalise across tasks. Annual Meeting of the Society for Mathematical Psychology, Tilburg. |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://mathpsych.org/conference/15/ |
| Description | Talk at Genetic FTD Meeting, Italy |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | International conference |
| Year(s) Of Engagement Activity | 2023 |
| Description | Tau2024 - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Immunophenotypes of PSP, CBS and FTD: blood versus brain?" - Tau2024 (Washington DC, 26/03/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | Telegraph on Florence Pugh visit to University of Cambridge with Race Against Dementia - Rowe Group |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Florence Pugh: 'Ever since I posted about dementia, so many people have reached out to me' When she's not busy with her hectic Hollywood schedule, the star is using her voice - and huge following - to support Race Against Dementia |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.telegraph.co.uk/christmas/2024/01/24/florence-pugh-oppenheimer-race-against-dementia-cha... |
| Description | Temporal structure in sensorimotor variability is a reliable trait, but is unrelated to attentional state measures. (Dr M Perquin - Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | • Oral talk at the Annual Meeting of the Society for Mathematical Psychology in Amsterdam, the Netherlands. The target audience of MathPsych is those interested in mathematical and computational theories of human cognition. Attendence was approx. 400-500. |
| Year(s) Of Engagement Activity | 2023 |
| Description | UKDRI Cambridge Seminar - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Inflammation in Frontotemporal Dementia: a multidisciplinary approach" UKDRI Seminar (Cambridge, 06/12/2024) |
| Year(s) Of Engagement Activity | 2024 |
| Description | UKDRI Neuro-immunology Theme - Dr Maura Malpetti (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | • "Inflammation in Frontotemporal Dementia: a multidisciplinary approach" UKDRI Neuro-immunology Theme Workshop (London, 04/02/2025) |
| Year(s) Of Engagement Activity | 2025 |
| Description | Understanding Dementia: Exploring the Brain - Dr Marlou Perquin (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | • Oral presentation at Pints of Science 2024, Cambridge at the session 'Understanding Dementia: Exploring the Brain'. The target audience is laypeople who are interested in neuroscientific research of dementia. Audience size was about 50 people. Perquin, M.N. (2024). Why are we variable? |
| Year(s) Of Engagement Activity | 2024 |
| Description | What's new in Frontotemporal Dementia - Sri Lankan Neurology Association |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk to Sri Lanka Neurology association "What's new in Frontotemporal Dementia?" |
| Year(s) Of Engagement Activity | 2023 |